Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 178.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,755 shares of the pharmaceutical company’s stock after purchasing an additional 3,047 shares during the period. Focus Advisor Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $2,486,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Community Financial Services Group LLC bought a new stake in Vertex Pharmaceuticals during the second quarter worth approximately $26,000. Meeder Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at approximately $26,000. MADDEN SECURITIES Corp bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Elevation Wealth Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 28 shares during the period. Finally, Pingora Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $32,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Royal Bank Of Canada raised their price objective on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. Jefferies Financial Group raised their price objective on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Finally, Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $596.44.

Check Out Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $514.75 on Friday. The firm has a market cap of $130.51 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 2.73 and a beta of 0.28. The firm’s 50 day simple moving average is $522.72 and its 200-day simple moving average is $485.26. Vertex Pharmaceuticals Incorporated has a one year low of $412.27 and a one year high of $568.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. Vertex Pharmaceuticals’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.80 earnings per share. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Sangeeta Bhatia sold 271 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the transaction, the director directly owned 4,653 shares in the company, valued at approximately $2,549,192.58. This trade represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $547,860.00. Following the transaction, the director directly owned 1,109 shares in the company, valued at approximately $607,576.74. The trade was a 47.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 16,557 shares of company stock valued at $9,071,071. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.